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Abstract
Correctly predicting off-targets for a given molecular structure, which would have the ability to bind a large range of
ligands, is both particularly difficult and important if they share no significant sequence or fold similarity with the respective
molecular target (‘‘distant off-targets’’). A novel approach for identification of off-targets by direct superposition of protein
binding pocket surfaces is presented and applied to a set of well-studied and highly relevant drug targets, including
representative kinases and nuclear hormone receptors. The entire Protein Data Bank is searched for similar binding pockets
and convincing distant off-target candidates were identified that share no significant sequence or fold similarity with the
respective target structure. These putative target off-target pairs are further supported by the existence of compounds that
bind strongly to both with high topological similarity, and in some cases, literature examples of individual compounds that
bind to both. Also, our results clearly show that it is possible for binding pockets to exhibit a striking surface similarity, while
the respective off-target shares neither significant sequence nor significant fold similarity with the respective molecular
target (‘‘distant off-target’’).
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Introduction
Searching for off-targets is very important for modern drug
design and for ongoing efforts to understand the complex
polypharmacology of well-known drugs. This search can be
performed either in a ligand- or target-focused way. In the former
case, the goal is to identify proteins to which an individual ligand
might bind. Approaches to this include topology comparisons of
ligands of different proteins and molecular receptor-ligand
docking. In case of target-centered off-target searches, which will
be the focus of this paper, the goal is to identify proteins (templates)
whose ligand binding criteria are very similar to the ones of the
molecular target of interest (query). Thus, many ligands of the
query protein could be expected to also bind to the template
protein.
Identification of off-targets in such a way would allow to
potentially speed-up and rationalize drug design in several ways:
drug targets that exhibit very many or very ‘dangerous’ off-targets
(i.e. those potentially leading to severe medical problems in the
patient), could be discarded as molecular targets. Alternatively, if a
protein with identified off-targets is selected as molecular target, an
emphasis can be placed in successive drug design steps to predict
and verify the behavior of drug candidates on all those off-targets
and inform the rational design of desired selectivity. In such way,
side-effects of drugs could be prevented or detected early-on, long
before entering clinical trails. Additionally, many rarer side-effects
(that depend on a population subgroup or use of other drugs)
might not even be encountered in clinical trials, but might in
principle be detectable this way. Last but not least, off-target
identification would also allow to better understand ligand
selectivity relationships between proteins and the reason for side-
effects of already commercially available drugs.
Several attempts have been made in the past to identify off-
targets of a given protein target. A number of authors [1–5] have
created fingerprints for description of the overall properties of a
pocket and quick comparison of pockets. Spitzer et al. [6] have
developed a procedure to compute surface similarities of
superposed proteins. This approach does not focus on performing
the actual superposition of the utilized proteins. As such, it can be
used in combination with simple backbone-based superposition
approaches or one of the procedures mentioned below in order to
assess the binding pocket surface similarity of closely related
proteins. In case of distant off-targets, it may on the other hand be
desirable to directly and efficiently superpose the surfaces, which is
the problem this paper focuses on. Similarily, Xie et al. [7] used a
Gaussian density function on Ca atoms to generate a statistical
description of the similarity of the pockets of two given proteins,
after employing a protein profile alignment based approach to
superimpose these proteins. These authors have used this
methodology for example to identify several nuclear hormone
receptors as putative off-targets of CETP inhibitors [8]. However,
due to the reliance of the method on sequence similarity, these off-
targets still retain reasonable sequence similarity to the respective
query protein.
Approaches performing an actual superposition of binding
pockets onto each other commonly use a set of pseudo-centers,
usually one per residue, to describe each pocket and then utilize a
graph-matching algorithm to find a mapping of template protein
pseudo-centers onto query pseudo-centers. The first such ap-
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proach was described in Kuhn et al. [9], which was modified and
extended in various way by several other authors [10–12].
However, all of those approaches display the same disadvantage
if the goal is to identify distant off-targets: these approaches might
suitably be described as local, pocket-centric fold comparison
algorithms. They do not focus directly on the binding pocket or its
surface, but use only a very rough representation in form of
pseudo-centers. The influence of side chains to the shape of the
binding pocket and to the ability of a ligand to bind to a protein,
are furthermore commonly ignored. Comparisons of what kind of
amino acids (or pseudo-centers) are found in what relative distance
to each other might reasonably be expected to infer knowledge
about local fold similarities of query and template proteins near
the binding pocket and can thus be expected to be helpful to detect
off-targets containing such a similarity to the query. While this is
definitely very useful, an even harder goal is finding potential off-
target that share neither significant sequence nor significant fold
similarity with the target of interest. Using the aforementioned
procedures towards this end would, for the described reason, most
likely not be helpful.
Najmanovich et al. [13], on the other hand, developed an
approach that uses graph-matching on all-atoms models of
binding sites. Therefore, this procedure is not prone to the
aforementioned problems acquired by a very rough description of
the binding pocket. Nonetheless, this approach in a first steps
explicitly searches the best superposition of template Ca atoms
onto query Ca atoms, and only performs all-atoms graph matching
on atoms that are near to each other as a result of the first step.
Thus, this method effectually is a backbone matching procedure
with subsequent minor, all-atom optimization. As such, it may be
interesting for some cases; not so however if the goal is to find
distant off-targets that share no fold similarity with the target
structure.
An interesting approach by Hoffmann et al. [14] uses an all-
atom model without utilizing a graph-matching. This procedure
therefore does not depend on fold similarity and should be able to
accurately model a pocket. However, the authors eliminate the
need for a mapping of template onto query atoms (as performed
by the aforementioned graph-matching algorithms) by simply
calculating the similarity between two pockets as the sum over all
distances between pairs of query and template atoms. This
similarity is then optimized by use of a graph-based procedure. In
order for a superposition of two pocket surfaces to be perfect, there
is in general of course no need for this sum over all pairwise
distances to be minimal. Thus, by use of this similarity for the
application of off-target finding, the authors make the assumption
that the entire template and query pockets are very similar with
respect to shape, size and distribution of atoms. If some of these
assumptions turn out to be false, as can reasonably be expected to
be the case for the large majority of all possible pocket pairs, the
approach, due to the utilized similarity function, has to end up
simply placing the template pocket at the center of mass of the
query pocket. This problem is furthermore aggravated by the fact
that binding pockets can have significantly different (automatically
determined) sizes and matching of sub-pockets is not possible this
way.
Here, we present an approach to finding distant off-targets by
direct superposition of protein binding pocket surfaces. We use a
well-established ligand selectivity data set to show that our
approach, although having being developed for detection of
distant off-targets, can predict close off-targets as well as the state-
of-the-art approach for that goal. We then apply our approach to a
set of well-studied target proteins, searching the entire PDB for
similar binding pockets, and for each of them thus reveal a
convincing distant off-target candidate that shares no significant
sequence or fold similarity with the respective target. Furthermore,
the usefulness of these off-target definitions is confirmed by
topology comparison of available, experimentally confirmed
ligands for the respective target and off-target.
Materials and Methods
Our approach superimposes two binding pockets, represented
by atoms contributing to their SES (solvent-excluded surface), and
afterwards scores the obtained superposition. We will first describe
how we automatically determine the size of a binding pocket and
will then explain how atoms are selected that should be used for
the subsequent matching step. Afterwards, we will outline how the
superposition is performed and how the final result is scored.
Note that if any water molecules are present near the ligand
(within a convex hull of 5 A˚) in the crystal structure, they will first
of all be protonated, rotationally optimized and only water
molecules that interact strongly with receptor and/or reference
ligand are retained. For details about this, please see Schumann
et al. [15].
Determination of binding pocket size
Since the definition of the boundaries of the binding pocket has
an impact on the following atom extraction step and since a
binding pocket can be significantly larger than the area next to a
specific reference ligand, we use an automatic procedure to
determine the binding pocket size.
First, spheres are placed above the receptor surface in positions
where they are deeply buried in the protein (i.e., in positions that
are located above the SES surface and that have a high number of
neighboring receptor atoms). We then sort these spheres according
to their ascending distance to the geometrical center of the
reference ligand. Starting with the sphere having the smallest
distance, we add spheres to our pocket definition as long they have
a distance smaller than 1.5 A˚ to at least one already selected
sphere. Placing a bounding box around all spheres obtained this
way reveals the size of the binding pocket. An example for the
determination of the binding pocket size is shown in Fig. 1.
Statistics about the size of the detected pockets of the query
proteins for our distant off-target searches are shown in Table S1
in the Supplementary Material.
The spheres obtained by this procedure will also be used to
define the solvent-exposed interior of binding pockets during the
surface superposition step, as described below.
Extraction of relevant surface atoms
In order to obtain the relevant binding pocket surface atoms, we
first compute the SES for the given protein. Then, all protein
atoms that do not contribute to the SES (according to a calculation
with Conolly’s analytical SES procedure [16]) are discarded.
Afterwards, we check for each remaining atom whether its
distance to the pocket bounding box (created as described above)
or a bounding box placed around the reference ligand is smaller
than 4 A˚.
Superposition of surfaces
In order to superpose template and query binding pocket
surfaces, we developed a modification and extension of Katchalski-
Katzir’s [17] approach to protein-protein docking. In contrast to
Kalchalski-Katzir, we will not aim to find the superposition
resulting in the best docking pose of two proteins, but the one
yielding the best binding pocket overlay.
Off-Target Search by Pocket Surface Superposition
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First, we transform the set of atoms and spheres obtained in the
previous steps into two separate three-dimensional grids (with a
resolution of 1 A˚) for query and template protein. Each cell of
these grids will contain information, represented by numerical
values, about whether its location is part of protein surface, directly
(1 A˚) above the surface, inside the binding pocket, or elsewhere on
the outside of the protein. The grids thus contain a detailed
representation of the three-dimensional shape and size of the
binding pockets.
Each cell of the grid for the query protein is filled according to
Eq. 1 in which x, y and z together denote a position in relative
atomic units. Here, a grid cell is regarded as being part of the
protein surface, if it has a distance smaller than 1.8 A˚ to any of the
query protein atoms selected in the previous step. Similarly, a cell
is defined as representing the interior of the binding pocket of the
query protein if this cell has a distance smaller than 1.8 A˚ to any of
the previously created spheres.
A(x,y,z)~
{5 pointpartofsurface
1 pointdirectlyabovesurface
5 pointinsidebindingpocket
0 else
0
BBBBBB@
ð1Þ
In a similar manner, a three-dimensional grid is filled for the
template protein according to Eq. 2.
B(x,y,z)~
{1 pointpartofsurface
1 pointdirectlyabovesurface
1 pointinsidebindingpocket
0 else
0
BBBBBB@
ð2Þ
A correlation score describing the quality of a potential
superposition obtained by transforming grid B according to a
given translation vector (a, b, c) and a given rotation r, can thus be
computed according to Eq. 3.
corr,a,b,c(A,B)~
PN
x
PN
y
PN
z
(A(x,y,z):
Br(xza,yzb,zzc))
ð3Þ
Values have been assigned to A and B in the way shown in
Equations 1 and 2 since they yield a positive correlation
contribution (according to Eq. 3) in cases when either surfaces
are matched onto each other or pocket areas are superimposed.
Overlaying a surface with a pocket area, on the other hand, will be
penalized this way, by means of a negative correlation contribu-
tion.
We then need to find the set of r, a, b and c that yields the
largest correlation value (Eq. 4). Naively, this could of course we
achieved by iterating over all possible translations (a,b,c~f1:::Ng)
and rotation angles (r~f1:::Kg). This would however require a
total of approximately K N6 compute steps, so that the run-time
using the naive implementation would in practice be much too
high.
best cor(A,B)~ argmax
r,a,b,c
corr,a,b,c(A,Br) ð4Þ
However, since a discrete Fourier transform (DFT) for a three-
dimensional function has the form shown in Eq. 5, we can, as
Katchalski-Katzir [17] discovered, utilize it to solve this kind of
problem more efficiently.
DFT(B)(a,b,c)~
PN
x
PN
y
PN
z
(B(x,y,z):
e{2p
ﬃﬃﬃﬃﬃ
{1
p
(axzbyzcz)=N )
ð5Þ
Thus, we can compute the correlation of A and B, depended
only on a given rotation, as
Cr~IFT(DFT
(A):DFT(Br)) ð6Þ
where IFT denotes the inverse Fourier transform and DFT the
conjugate of the DFT. Fourier and inverse Fourier transformations
can be performed by the fast Fourier transform algorithm [18]
Figure 1. Pocket size detection. left) reference ligand in binding pocket; center) Place spheres in positions where they are relatively deeply burial
in the receptor; right) Final pocket description, obtained by iteratively selecting spheres that are near to previously selected spheres, starting at
geometrical center of ligand.
doi:10.1371/journal.pone.0083533.g001
Off-Target Search by Pocket Surface Superposition
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(FFT), which requires only about N3:ln(N3) steps to transform our
functions.
Thus, the best correlation can be found by only iterating over all
rotations (instead of iterating over all translations and rotations, as
shown in Eq. 4)
best cor(A,B)~ argmax
r,a,b,c
Cr(a,b,c) ð7Þ
Values r, a, b and c that yield this result are the optimal rotation
and translation steps, respectively. In total, superposing the two
grids this way hence requires only on the order of K :N3:ln(N3)
compute steps. For our evaluations, we discretize the rotations
around the global X, Y and Z axis into steps of 20u. Run-time for
superposing two binding pocket surface thus amounts to approx-
imately ten seconds (on an AMD Opteron 6134).
Scoring of superposition
To obtain a similarity score for two given binding pockets, we
apply the best superposition found in the previous step and then
compute the fraction of query surface that was matched to
template surface and then we penalize for query pocket areas
obscured by template protein:
sim~
Qmat
Qtot
: 1{
Sobs
Stot
 2
ð8Þ
Here, Qmat denotes the number of query surface atoms that
have at least one template pocket surface atom within a distance of
1.8 A˚ and Sobs (obscured pocket spheres) denotes the number of
query pocket spheres having at least one template surface atom
within a distance of 1.4 A˚. The total number of query surface
atoms is represented by Qtot, and the total number of query pocket
spheres by Stot.
Availability
Created software tools are freely available as part of our
computer-aided drug design suite (CADDSuite) at http://
caddsuite.github.com.
Results/Discussion
Closely related off-targets
Although our approach is aimed at finding distant off-target that
share no significant sequence or fold similarity with the respective
target structure, we first of all evaluate our procedure on the data
set utilized by Milletti [12] in order to show that we can indeed
also adequately find relatively closely related kinase-kinase off-
targets. This data set, a subset of the Ambit 2008 [19] panel,
contains activity data for 17 compounds on 189 kinases, obtained
by in vitro competition binding assays [19]. Given a co-crystal
structure of a kinase with an inhibitor, the goal here is to predict
which other kinases act as off-targets for the respective target
structure.
Comparison of the performance of our approach with the one
by Milletti [12] as shown in Figure 2 in blue vs. gray, proves that
we can predict close off-targets as well as the state-of-the-art
approach for that goal. The average ROC AUC of Milletti over
the 17 query pockets is 0.64, and our performance of 0.63 is not
significantly different. (ROC curves for the individual targets are
shown in Figure S1 in the Supplementary Material.)
However, is has to be noted that Milletti’s ‘‘ligand centered’’
way of defining true off-targets may be considered suboptimal for
evaluation of binding pocket comparisons. Milletti classifies a
protein as a true off-target if the affinity of the target structure
ligand to it was lower than 10 uM. The goal of pocket
comparisons on the other hand is to find proteins that display a
very similar binding pocket and might thus serve as off-target for a
range of ligands, not just one particular ligand. As specificity of
binding can vary considerably between different ligands, we
perform a separate analysis of our results taking into account all
ligands with available binding affinity data for target and off-target
candidate. In our ‘‘target centered assessment’’, we classify a
protein as a true off-target, if it shares with the target protein at
least half of their nano-molar inhibitors. Our average ROC AUC
for all 17 query pockets, obtained by this target centered analysis,
is 0.676. This shows that, even according to this more appropriate
metric, our approach is able to find closely related off-targets well.
It is furthermore noteworthy that comparing results obtained by
ligand vs. target centered analysis may be interesting in order to
try to infer some knowledge about ligand selectivity and
promiscuity. In eight out of 17 cases (1M17, 3BLR, 3GVU,
1UU3, 1UNL, 3G0F, 2F4J, 2IVU), the ROC AUC (receiver-
operating characteristic area-under-the-curve) obtained by target
centered analysis (shown in orange in Figure 2) was much larger
than the one obtained with ligand centered assessment. This
difference is most likely is due to strong and specific binding of the
respective reference ligand to the target structure, whereas many
other ligands bound less selectively. Therefore, the reference
ligand, in contrast to other ligands, may not bind to most other
examined proteins that do exhibit high binding pocket surface
similarity. On the other hand, in three cases (3FZS, 2EWA,
1NVR) the quality was judged to be less good with the target
centered analysis. Here, the explanation may lie in less selective
binding of the reference ligand, compared to all other ligands of
the respective target. This explanation can be easily rationalized
by considering 1NVR, which is a co-crystal structure of
staurosporine, the single most promiscuous kinase inhibitor. Thus,
many ligands of the respective target may not bind to other
examined proteins that show significant surface similarity, whereas
the reference ligand was able to do so.
Distant off-targets
In order to analyze the performance of our approach for
identification of distant off-targets, we select a number of well-
studied, medically relevant, kinase and non-kinase proteins as
Figure 2. Evaluation of performance for identification of
closely related off-targets of our approach (blue, orange) in
comparison to Mellitti’s [12] procedure (gray).
doi:10.1371/journal.pone.0083533.g002
Off-Target Search by Pocket Surface Superposition
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target structures and investigate whether we can find interesting
and meaningful distant off-targets for them.
Therefore, binding pockets for all co-crystal structures in the
PDB containing a ligand with a molecular weight between 300
and 800 g/mol are prepared in the aforementioned way. Each
query pocket, after having being processed in a similar way, is then
matched to each obtained PDB pocket (template) by our
algorithm. Template proteins exhibiting a sequence identity
greater than 40% or a secondary structure identity greater than
60% are ignored in these experiments in order to simplify the
analysis of results since our goal is to find distant off-targets.
Secondary structure identity is hereby calculated as the fraction of
residues being part of an identical secondary structure type
according to DSSP [20] after global alignment of query of
template protein sequence. All superpositions generated for one
query protein are subsequently ranked according to their pocket
similarity scores as shown in Eq. 8. The approximately best ten
matches are then analyzed manually in order to confirm surface
similarity and fold dissimilarity.
For all examined query proteins, we could identify template
proteins that share neither significant sequence nor fold similarity
with the target but exhibit a high binding pocket surface similarity.
In the following, we will discuss the results for all performed pocket
searches. We will in each case describe the, in our opinion,
(A) CLK3 (green) and PPARγ (blue)
(B) VEGFR2 (green) with sorafenib and DHFR (blue)
(C) KIT (green) with sunitinib and HIV-1 protease (blue)
(D) CK2α (green) with emodin and DNA topoisomerase I (blue)
(E) PDE5A (green) with sildenafil and phospholipase A2 (blue)
Figure 3. Identification of distant off-target candidates by search of PDB pockets. The query protein is shown in green; the template
protein in blue. Columns 1–3 show the binding pocket surfaces of query, template, template and query, respectively, together with the query
structure’s reference ligand. Were necessary, surfaces have been cut open for better view. Column 4 depicts the fold dissimilarity near the binding
pocket. Part 1 of 2.
doi:10.1371/journal.pone.0083533.g003
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medically most relevant off-target candidate. Each of them was
encountered at the very top of the rank list (within the
approximately top 10). To further strengthen the suggested
connection between target and off-target, we will then compare
experimentally confirmed strong binders (affinity lesser than
5 mM) of the target with those of the off-target using data available
in BindingDB [21]. The basic intent of these searches for similar
binding pockets is, as mentioned before, to find proteins that could
realistically acts as off-target for a range of ligands of a given
molecular target, not to predict the binding or selectivity of any
individual ligand.
CLK3. The first search for potential distant off-targets is
performed for CDC-like kinase 3 (CLK3). CLK3 acts as a dual
specificity, serine/threonine and tyrosine kinase that phosphory-
lates serine- and arginine-rich splicing factors and is thus assumed
to be involved in the regulation of mRNA splicing and alternative
splicing [22,23].
Analysis of the results obtained for CLK3 (PDB ID 2WU6)
shows a striking similarity, shown in Figure 2a, of its binding
pocket to the one of peroxisome proliferator-activated receptor
gamma (PPARc, PDB ID 3R8I). PPARc is a nuclear receptor that
activates the acyl-CoA oxidase transcription and thereby has a
important impact on fatty acid metabolism [24]. CLK3 and
PPARc show a very low sequence identity of only 23% but their
binding pockets exhibit a very similar shape and size. Further-
more, the folds of the two proteins near the superposed binding
pockets are completely dissimilar, as can be clearly seen in
Figure 3a (See also Figure 4). Thus, PPARc may be considered a
distant off-target candidate for CLK3. Comparison of known
strong binders for CLK3 with those for PPARc reveals
compounds, shown in Figure 5a, with a very high topological
similarity. Furthermore, this pair of ligands is also very similar to
reference ligand in the utilized co-crystal for CLK3. Taken
together, these findings indicate that it may be very helpful to
consider PPARc as an off-target when trying to develop drugs for
CLK3 (or vice versa) and thus try to predict and/or experimen-
tally measure the affinity of potential drug candidates to both
proteins.
Furthermore, in other pocket searches, we have observed
numerous examples of similarity between other human kinase
enzyme pockets (that are themselves similar to our CLK3 query
protein 2WU6) and PPARc. Thus, we hypothesize that various
classes of kinase inhibitor scaffolds may have the potential to
exhibit PPARc partial agonist activity. One literature example of a
drug candidate molecule that displays this behavior is ertiprotafib,
which was initially developed as a PTP1B inhibitor, and later
found to act as partial agonist of PPARc [25,26] and potent
inhibitor of IkappaB kinase beta (IKK-beta) [27].
Observations regarding other drug classes also help to
substantiate the hypothesis that the binding pocket of PPARc
exhibits remarkable flexibility resulting in high pocket similarities
to a significant number of other unrelated proteins. The
sulfonylurea class of commonly prescribed antidiebetic agents
(glipizide, glyburide, glimepride) primarily target the sulfonylurea
receptor stimulating insulin release, where the thiazolidinedione
class of antidiebetic agents (pioglitazone) primarily act as partial
agonists of PPARc improving insulin resistance through the
transcription of the insulin-sensitive genes involved in the control
of glucose and lipid metabolism. A very interesting paper by Scarsi
et al. [28], demonstrated convincing evidence that glipizide (the
most commonly prescribed of the sulfonylurea class) exhibits
PPARc partial agonist activity as well as having primary activity at
the sulfonylurea receptor, thus showing Glipizide’s theraputic
efficacy may have origins in dual activity for both drug targets.
Interestingly, there is recent evidence from the literature for
biologically relevant PPARc partial agonist off-target activity for
examples from three other different major drug target classes.
Partial agonist activity for PPARc has recently been reported for
an angiotensin receptor antagonists (telmisartan) [29], the most
commonly used ACE inhibitor (lisinopril) [30, 31], and in the
COX 1/2 inhibitor indomethacin [32]. The observation that
drugs from four different classes (glipizide, telmisartan, lisinopril,
and indomethacin) all exhibit partial agonist activity for PPARc,
support our observation that agonist-bound conformations of the
PPARc pocket in particular may exhibit similarity to other drug
target pockets.
VEGFR2. Vascular endothelial growth factor receptor 2
(VEGFR2) is a tyrosine protein kinase that serves as a receptor
for growth factors and thus has a strong influence on endothelial
cell growth, migration and differentiation [33].
The VEGFR2 binding pocket (as observed in PDB entry 4ASD)
is revealed by our approach to have a very high similarity, shown
in Figure 3b, to the one of dihydrofolate reductase (DHFR, PDB
ID 3SA1). DHFR converts dihydrofolic acid to tetrahydrofolic
acid, a key step in the folic acid pathway that is necessary for
generation of precursors of DNA and glycine [34]. Sequence
identity between the utilized VEGFR2 and DHFR structures is
just 22% and Figure 3b furthermore reveals that the two proteins
(F) estrogen receptor β (green) with estradiol and carbonic anhydrase II (blue)
(G) glucocorticoid receptor (green) with dexamethasone and ileal lipid binding protein (blue)
Figure 4. Identification of distant off-target candidates by search of PDB pockets. Part 2 of 2.
doi:10.1371/journal.pone.0083533.g004
Off-Target Search by Pocket Surface Superposition
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share no fold similarity that could serve as a trivial explanation for
the high observed pocket similarity. Although it is not the intent of
our procedure to predict the activity of individual compounds, it is
noteworthy that the VEGFR2 reference ligand, sorafenib, seems
in principle to be well accommodated by the DHFR pocket. Even
if sorafenib itself turned out not bind to DHFR in vivo, this still
visualizes that DHFR might act as off-target for other compounds
(related to sorafenib) that act on VEGFR2 (or vice versa). This
connection between VEGFR2 and DHFR is also strengthened by
the fact that some very similar ligands, depicted in Figure 5b, have
already been proven to bind to either of them with similar affinities
(2 mM and 1.9 mM, respectively). A superposition of the DHFR
pocket that was found in the search (PDB ID 3SA1) with the E and
Z derivatives of the compound shown in Figure 5b (PDB ID 3K45
and 3K47) [35] bound to human DHFR shows that the binding
modes of all three DHFR inhibitors are quite similar within the
pocket that was matched in the search. The authors of the crystal
structures [35] are rationally developing these compounds as dual
inhibitors of tyrosine kinases and DHFR.
KIT. KIT is a tyrosine protein kinase acting as a receptor for
cytokines that is involved, via various pathways, in (among others)
cell survival, migration, differentiation and melanogenesis [36].
A strong binding pocket similarity is detected utilizing our
approach between KIT (PDB ID 3G0E) and HIV-1 protease
(HIVPR, PDB ID 3NLS), as can be seen in Figure 3c. HIVPR
cleaves polyproteins of human immunodeficiency virus (HIV) into
separate proteins that then make up the viral envelope (virion) of
HIV and is thus necessary for HIV infectivity [37]. The KIT and
HIVPR structures exhibit a sequence identity of only 21% and no
fold similarity (see Figure 3c). The observed pocket of HIVPR is
slightly shorter than the KIT pocket in the direction of the
fluorobenzene group of sunitinib shown in the superpositions, but
otherwise displays very high similarity. Thus, it might be desirable
to keep KIT in mind as potential off-target when trying to develop
drug for HIVPR. Figure 5c furthermore shows that indeed a
compound that is very similar to the HIVPR inhibitor indinavir
has already been proven to strongly bind to KIT. The affinities of
both molecules are in the low nano-molar range (0.24 nM in case
Figure 5. Known ligands for each of the query proteins, together with known ligands of each suggested off-target.
doi:10.1371/journal.pone.0083533.g005
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of indinavir [38] and 5.7 nM [38] in case of the similar KIT
inhibitor). In addition, a very interesting paper by Xie et al. [39],
has recently computationally identified and then experimentally
verified that the HIVPR inhibitor nelfinavir indeed demonstrates
the ability to inhibit multiple kinases.
CK2 a. Casein kinase II subunit alpha (CK2a) is the catalytic
subunit of casein kinase II, a serine/threonine protein kinase
complex involved in many signaling cascades, including some
affecting cell cycle progression [53] and apoptosis [54].
Application of our pocket comparison approach reveals, as
shown in Figure 3d, that the pocket of DNA topoisomerase I (as
encountered in PDB entry 1SEU) has a highly similar shape and
size, compared to the CK2a binding pocket (PDB ID 3Q9X).
DNA topoisomerase I creates single-strand cuts of DNA and
subsequent reconnection after release of DNA supercoiling. Thus,
DNA topoisomerase I is important for DNA replication. CK2a
and DNA topoisomerase I share a sequence identity of only 21%
and no fold similarity, as depicted in Figure 3d, that could explain
the highly similar pockets. Examination of known CK2a and DNA
topoisomerase I binders furthermore revealed very similar
compounds (see Figure 5d), both of which are related to
staurosporine, that have been shown to bind with similar affinities
to either of the two proteins. The superposition of the human
topoisomerase I structure bound to the staurosporine related
indocarbazole shown in Figure 5d (PDB ID 1SEU) [55], with the
structure of the FDA approved drug hycamptin (PDB ID 1K4T),
reveals that the pocket match is to the biologically relevant binding
mode of the camptothecin class of topoisomerase I poisons [55].
PDE5A. Phosphodiesterase 5A (PDE5A) is a phosphodiester-
ase that converts cGMP into GMP and is thereby (among others)
involved in the relaxation of smooth muscles [56].
A very high pocket similarity, displayed in Figure 3e, is revealed
by our approach between the sildenafil-bound PDE5A pocket
(PDB ID 1TBF) and the binding pocket of phospholipase A2
(PLA2, PDB ID 1FXF). Phospholipase A2 hydrolyzes the sn-2 acyl
bond of arachidonyl phospholipids, releasing arachidonic acid. Its
function is implicated in the initiation of the inflammatory
response and thus has been the target of drug discovery efforts
[57] for anti-inflammatory agents, especially for neurological [58]
and cardiovascular [59,60] indications. PDE5A and PLA2 contain
only 20% sequence identity have no fold similarity near the
superimposed pockets, as can be seen in Figure 3e. Also, molecules
with significant topological similarity to each other and to
sildenafil are known to bind strongly to PDE5A, respectively
PLA2 (see Figure 5e).
Phospholipase A2 inhibition has also been identified as off-
target activity in some commonly used drugs. Non-pancreatic
secretory phospholipase A2 (membrane associated) is inhibited by
diclofenac [61,62], and cytosolic phospholipase A2 is inhibited by
the commonly prescribed corticosteroid fluticasone propionate
[63,64], as well as epirubicin [65] and niflumic acid [66].
Estrogen receptor b. Estrogen receptor b (ERb) is a nuclear
receptor that activates the transcription of genes containing
estrogen response elements. Its estradiol-bound pocket (PDB ID
3OLL) is shown by our pocket comparison to be highly similar (see
Figure 4f) to the pocket of carbonic anhydrase II (CAII, PDB ID
3OKV). CAII is no nuclear steroid receptor but the ubiquitous
enzyme that catalyzes the conversion carbon dioxide to carbonic
acid. As such, it shares only a sequence identity of 24% with ERb.
Furthermore, the high pocket similarity is not the result of any
significant fold similarity, as is clearly visualized in Figure 4f.
In contrast to all results discussed before, the ligand observed in
the co-crystal structure of the target and the one in the structure of
the suggested off-target have a very similar topology. Both
compounds are derivatives of estrogen. Therefore it is of interest
that the obtained pocket superpositions resulted in very close poses
for two ligands, shown in Figure 6. In cases in which reference
ligands of target and suggested off-target are highly similar, a
simply querying of the PDB for a given ligand topology could
arguably have yielded similar results. However, doing so would not
elucidate whether binding of similar ligands by target and off-
target is due to ligand promiscuity or binding pocket similarity.
Since we, after having used our pocket superposition based search,
now know that the pockets of ERb and CAII can assume very
similar shapes, we searched their respective BindingDB [21] data
sets for other known topologically similar ligands. We indeed
found strong inhibitors of CAII that are highly similar to strong
antagonists of ERb and that are not steroids, displayed in Figure 5f.
Glucocorticoid receptor. Glucocorticoid receptor (GR) is a
nuclear receptor regulating the transcription of genes containing
glucocorticoid response elements that is thereby involved in
modulating inflammatory response and other processes.
As can be seen from Figure 4g, the dexamethasone-bound
binding pocket of GR (PDB ID 3MNP) was found by our pocket
Figure 6. Crystal structure pose of estradiol in 3OLL (green) in
comparison to the pose of the ligand of 3OKV obtained by
superposing the latter onto the former by use of our
algorithm.
doi:10.1371/journal.pone.0083533.g006
Figure 7. Dexamethasone as observed in 3MNP (green) in
comparison to taurocholic acid in 1O1V after superposition of
the two pockets by our approach.
doi:10.1371/journal.pone.0083533.g007
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comparison to be highly similar to the pocket of ileal lipid binding
protein (ILBP, PDB ID 1O1V). ILBP is involved in the
transportation of bile acids. While bile acids as well as
glucocorticoids are steroids and thus this pocket search result
may come at no surprise, this example visualizes that our pocket
matching approach correctly superposes binding pockets that are
known to bind near identical ligands. The very low deviation
between the pose of the ILBP ligand and the GR-bound
dexamethasone pose, obtained after applying our pocket super-
position, is shown in Figure 7. Although the ligands of these two
proteins are, as stated, very similar, the pocket surface superpo-
sition was not trivial, since both proteins have a sequence identity
of only 23% and, as Figure 3g makes clear, share no fold similarity
that might have produced the high pocket similarity.
Comparison to other methods. As described above, and as
can be seen in Figures 3–4, all of our distant off-target matches
exhibit no significant backbone and no significant fold superpo-
sition. Thus, the use of an accurate description of the binding
pocket was important here for the superposition, so that simpler
approaches, for example, Ca atom-based procedures, would not
have sufficed to find these off-targets. To furthermore substantiate
this, we now perfomed all pocket superpositions between target
and repective proposed distant off-target using only Ca atoms.
Thus, all previously utilized residues are now used as well, but
instead of using all atoms that contribute to the pocket surface (and
pocket spheres), we now used only those residues’ Ca atoms.
Afterward performing the superpositions, they are scored in the
normal way, according to Eq. 8. The average pocket superposition
score when using only Ca atoms for the matching, was 0.095,
compared to 0.614 when using the normal superposition
approach. (Scores for individual superpositions are shown in
Table S2 in the Supplementary Material.) Visual examination
furthermore showed that when using only Ca atoms for the
superposition, the interior of the superposed off-target protein
obscured large parts of the target’s pocket (or vice versa), rendering
these Ca atom-based superpositions practically useless. This
confirms that inclusion of an accurate pocket (surface) description,
utilizing all relevant atoms (including side chain atoms), was
crucial for identification of the off-targets proposed here.
Additionally, we checked whether existing approaches would
have found any of the presented distant off-targets. Note however,
that existing approaches cannot be reasonably excepted to
discover distant off-targets, since they were not designed for this
and since they, in constrast to our method, rely on sequence- or
fold similarity, as explained in the introduction. First, we used
PoSSuM [5] (http://possum.cbrc.jp/PoSSuM/) without a limit
for the maximum number of hits to be reported, and searched the
entire PDB database for protein pockets similar to each of our
seven query proteins. For all seven cases, PoSSuM did not find the
off-target of the respective query protein. Next, we utilized ProBis
[11] (thttp://probis.cmm.ki.si) to individually compare each of our
query pockets to its respective presented off-target pocket. For six
out of seven cases, ProBis detected no similarity at all. In the case
of CK2a, ProBis found only a very low pocket similarity to DNA
topoisomerase I (z-score of 1.08). The three-dimensional super-
position of these two proteins generated by ProBis furthermore
mapped the CK2a pocket onto the interior of DNA topoisomerase
I, showing that no meaningful pocket similarity could be detected.
Conclusions
In this paper, we presented a new approach for identification of
distant drug off-targets. Protein atoms near the binding pocket
surface and information about the location of the interior of the
binding pocket are converted into numerical values and stored in a
three-dimensional grid. Performing this step separately for query
and template protein results in two grids, a multiplication of which
yields a score for a potential superposition of the pockets of the two
proteins. Fast Fourier transformation is then utilized to speed-up
the search for the best superposition by about three orders of
magnitude compared to a naive implementation and thus allows
for fast and efficient comparison of binding pockets.
We demonstrated that our approach is able find convincing
distant off-target candidates that share no significant sequence or
fold similarity with the respective molecular target. The connec-
tion between targets and suggested off-targets was additionally
strengthened by the high topological similarity between some
known strong binders of the target and the respective off-target,
and by literature examples of ligands that exhibit experimentally
confirmed activity to both respective proteins.
Thus, applying our approach in order to derive a list of off-
target candidates to be taken into account if trying to develop new
drugs may be very helpful. By doing so, the affinity of each drug
candidate to the suggested off-target can then be predicted or
experimentally measured. Drug candidates that are detected to
strongly interact with off-targets can hence be cast aside,
potentially speeding-up the process of development of new drugs
and helping to evade side-effects and toxicity. Furthermore,
significant flexibility of the query protein is not by itself
problematic due to two important methodological reasons. First,
our approach will always determine the best superposition of two
pockets, even if this results in only parts of the two pockets being
matched onto each other. Secondly, since we always search the
entire PDB database for similar template pockets, the search itself
allows for significant flexibility between different templates.
However, problems can arise if the template protein belongs to
a class of proteins for which there are only very few structures in
the PDB data base (e.g., transmembrane proteins). If it is suspected
that a given protein has (distant) off-targets that belong to such a
class, it might be of interest to perform the search as described in
this manuscript step-by-step for different parts of the pocket. A
variety of different techniques (e.g., elastic network models,
molecular dynamics) could be used to assess the flexibility of
different parts of the query pocket. For example, a search could
thus begin with the most static query pocket region, and
subsequent searches could be performed using diverse conforma-
tional states of other parts of the query pocket.
Although the presented approach, in its current form, is aimed
at finding off-targets that could potentially bind a large range of
target ligands and not to study individual compounds, future
combinations of this approach with successive molecular docking,
scoring and/or ligand pose optimizations (e.g. energy minimiza-
tions) could allow to also investigate the potential behavior of
individual ligands in more detail.
Supporting Information
Figure S1 ROC curves showing the performance of our
approach on identification of close off-targets for all 17
of Milletti’s [12] data sets. Results for target-centered
evaluation are shown in blue, results for ligand-centered
evaluation in orange (see text for explanation).
(PDF)
Table S1 Size and number of residues contributing to
pocket surface for all query proteins used for our distant
off-target searches.
(PDF)
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Table S2 Scores for distant off-target pocket superpo-
sitions performed by our approach in the normal way,
in comparison to when using only Ca atoms for the
superpositions. Superposition scores were calculated as shown
in Eq. 8.
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